Best Pharma Stocks Under 200

The below table shows the Best Pharma Stocks Under 200 based on the Highest Market Capitalization.

Content:

• What Are Pharma Stocks?
• Best Pharma Stocks Below 200
• Pharma Stocks Under ₹200
• Top Pharma Stocks Below 200
• Best Pharma Stocks Below 200
• Features of Pharma Stocks Below 200
• How To Invest In Pharma Stocks Below 200?
• Introduction to List Of Pharma Stocks Below 200
• Best Pharma Stocks Under 200 – FAQ

What Are Pharma Stocks?

Pharma stocks represent companies involved in the research, development, production, and marketing of medications and medical products. These stocks are part of the pharmaceutical sector, which is considered defensive, often maintaining stability during economic downturns due to constant demand for healthcare services.

Investing in pharma stocks can offer steady returns, as the industry is less sensitive to economic cycles compared to others. These stocks might also provide dividends, appealing to income-focused investors.

However, pharma stocks are subject to regulatory risks and high costs associated with drug development. Changes in healthcare policies and patent expirations can also significantly impact their performance.

Best Pharma Stocks Below 200

The table below shows Best Pharma Stocks Below 200 based on 1 Year Return.

Pharma Stocks Below 200 in India

The table below shows Pharma Stocks Under ₹200 based on 1 Month Return.

Top Pharma Stocks Below 200

The table below shows Top Pharma Stocks Below 200 based on the highest day Volume.

Best Pharma Stocks Below 200

The table below shows the Best Pharma Stocks Below 200 based on the PE Ratio.

Features of Pharma Stocks Below 200

The main features of pharma stocks below ₹200 include affordability for retail investors and the potential for high returns. These stocks often belong to smaller companies, which might present faster growth opportunities but also carry higher risks due to volatility and regulatory challenges.

• Affordable Entry: Pharma stocks priced below ₹200 are accessible to a wider range of investors, allowing for portfolio diversification without significant capital. This lower entry point makes it easier for individual investors to buy more shares and potentially leverage market movements.

• High Growth Potential: These stocks often belong to smaller, more dynamic pharmaceutical companies poised for rapid growth. While they offer the chance for significant returns, this comes with the risk of higher volatility due to their smaller market capitalizations and less established products.

• Regulatory Roulette: Investing in these stocks requires careful consideration of regulatory impacts. Approval or rejection of new drugs by bodies like the FDA can drastically affect a company’s stock price, making these investments particularly susceptible to regulatory news.

• Market Volatility: Due to their lower price and smaller size, these stocks can be more volatile than those of larger pharmaceutical companies. This can lead to significant price swings, offering both substantial gains and losses, depending on market conditions and investor sentiment.

How To Invest In Pharma Stocks Below 200?

To invest in pharma stocks below ₹200 using Alice Blue, identify potential companies, open an account, and allocate funds. Leverage their research tools to scrutinize financials, drug pipelines, and market trends, ensuring the stocks align with your investment goals.

Focus on companies with strong product pipelines and regulatory approval prospects. Analyze their financial health and potential for future growth, considering their smaller size and market dynamics.

Diversify your investments to manage risk. Monitor your portfolio regularly, responding to market changes and regulatory updates that could impact stock performance.

Introduction to List Of Pharma Stocks Below 200

Marksans Pharma Ltd

The Market Cap of Marksans Pharma Ltd is Rs. 7,633.54 crores. The stock’s monthly return is 0.90%. Its one-year return is 82.66%. The stock is 15.34% away from its 52-week high.

Marksans Pharma Limited is an India-based pharmaceutical company engaged in research, manufacturing, marketing, and selling pharmaceutical formulations. The company produces goods across various therapeutic areas, including pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic.

Marksans Pharma operates four manufacturing facilities in India, the United Kingdom, and the United States. In Goa, the company manufactures oral solid tablets, soft gelatin capsules, and hard capsules. It also produces non-sterile liquids, ointments, and powders in the UK, catering to the UK, West Africa, and the Middle East. In the US, it has a facility spread over 7,000 square meters for tablet and capsule production.

Valiant Laboratories Ltd

The Market Cap of Valiant Laboratories Ltd is Rs. 645.88 crores. The stock’s monthly return is 0.44%. Its one-year return is -11.76%. The stock is 45.38% away from its 52-week high.

Valiant Laboratories Limited is an India-based company specializing in the manufacturing of active pharmaceutical ingredients (APIs). The company deals in specialty chemicals and pharma intermediates both domestically and internationally. It primarily focuses on producing paracetamol API, used to treat headaches, muscle aches, arthritis, backaches, toothaches, colds, and fevers.

Valiant Laboratories operates a single manufacturing facility located in the Tarapur industrial estate, approximately 150 kilometers from Nhava Sheva Port (JNPT). The company also has a subsidiary, Valiant Advanced Sciences Private Limited, which supports its operations and growth in the pharmaceutical sector.

Denis Chem Lab Ltd

The Market Cap of Denis Chem Lab Ltd is Rs. 248.95 crores. The stock’s monthly return is -8.81%. Its one-year return is 110.37%. The stock is 7.70% away from its 52-week high.

Denis Chem Lab Limited is an India-based pharmaceutical company engaged in manufacturing pharmaceutical transfusion solutions in bottles. The company offers a range of sterile intravenous injectables for human and veterinary use, including carbohydrate solutions, sodium chloride solutions, and multi-electrolyte solutions.

Denis Chem Lab Limited produces sterile intravenous injectables in volumes from 100 milliliters to 10 liters. In addition to selling its own branded products, the company manufactures on a contract basis for third parties, including multinational pharmaceutical companies. The product range includes antibiotics, dialysis solutions, and plasma volume expanders.

Lactose (India) Ltd

The Market Cap of Lactose (India) Ltd is Rs. 176.56 crores. The stock’s monthly return is 30.36%. Its one-year return is 290.19%. The stock is 5.89% away from its 52-week high.

Lactose (India) Limited is an India-based pharmaceutical company involved in manufacturing, trading, and job work for pharmaceutical products. The company specializes in producing lactose monohydrates and offers products in various segments, including liquid dosage forms, solid dosage forms, excipients, and active pharmaceutical ingredients.

Lactose (India) Limited also manufactures disaccharide lactulose and dry granulated, film, and lacquer-coated tablets. The company produces pharma color coatings with an installed capacity of approximately 180 metric tons per annum. Additionally, it offers prebiotic galacto-oligosaccharides (GOS) for use in dairy products, beverages, bakery products, infant and clinical nutrition, and geriatric nutrition. The company’s plant is located in Taluka Savli, Vadodara, Gujarat.

Sanjivani Paranteral Ltd

The Market Cap of Sanjivani Parenteral Ltd is Rs. 213.76 crores. The stock’s monthly return is -0.31%. Its one-year return is 149.47%. The stock is 17.15% away from its 52-week high.

Sanjivani Paranteral Limited is engaged in manufacturing pharmaceutical products. Its product categories include antibiotics, anti-emetics, NSAIDs, analgesics, antimalarials, calcium and vitamins, sedatives, steroids, cardiovascular drugs, antifibrinolytics, anti-coagulants, vasoconstrictors, inotropic agents, antispasmodics, multivitamins, nutrition, and iron supplements.

Sanjivani Paranteral Limited’s antibiotic range includes Netilmicin Sulphate, Amikacin Sulphate, and Gentamycin Sulphate. Anti-emetics feature Ranitidine Hydrochloride, Metoclopramide, Ondansetron, and Promethazine. NSAIDs and analgesics include Acetaminophen Injection and Diclofenac Sodium Injection. The calcium and vitamin category comprises Methylcobalamin 500 mcg/ml and Nicotinic Acid 10 mg/ml, while sedatives include Midazolam Hydrochloride, Diazepam, and Dobutamine Hydrochloride.

Smruthi Organics Ltd

The Market Cap of Smruthi Organics Ltd is Rs. 200.65 crores. The stock’s monthly return is 1.72%. Its one-year return is 24.45%. The stock is 29.47% away from its 52-week high.

Smruthi Organics Limited is an India-based active pharmaceutical ingredients (API) manufacturer serving pharmaceutical companies. The Company’s segments include Bulk Drugs, Drug Intermediates, and Formulation. It specializes in anti-diabetic, anti-hypertension, and anti-infective therapeutic categories, producing APIs like Amlodipine Besilate, Losartan Potassium, and Metformin HCL.

Smruthi Organics caters to both Indian and global markets, with clients across Asia, the Americas, and Africa. The Company operates two manufacturing facilities in Solapur, India, with the API facility spread over 22 acres. Their product portfolio includes Vildagliptin, Teneligliptin, Ciprofloxacin HCL, and more.

Vaishali Pharma Ltd

The Market Cap of Vaishali Pharma Ltd is Rs. 168.89 crores. The stock’s monthly return is -10.18%. Its one-year return is 19.28%. The stock is 33.14% away from its 52-week high.

Vaishali Pharma Limited is an India-based pharmaceutical company engaged in the domestic and export markets. The company deals in pharmaceutical ingredients, formulations, surgical products, herbal and nutraceutical products, and veterinary supplements. Its product categories include active pharmaceutical ingredients (APIs), formulation brands, herbal, nutraceuticals, oncology, surgical, and veterinary products.

Vaishali Pharma Limited offers a range of APIs, including antibiotics, anti-ulcer, anti-inflammatory, anti-malarial, cardiac, anti-diabetic, anti-allergic, anti-diarrheal, antiviral, anti-epileptic, anti-asthmatic, antifungal, antiplatelet, skeletal muscle relaxants, and anti-helmintic drugs. The company markets approximately 1,500 products and has over 200 brands in around 35 countries.

Auro Laboratories Ltd

The Market Cap of Auro Laboratories Ltd is Rs. 146.56 crores. The stock’s monthly return is -6.61%. Its one-year return is 139.16%. The stock is 46.15% away from its 52-week high.

Auro Laboratories Limited is an India-based manufacturer specializing in active pharmaceutical ingredients (APIs), intermediates, and generic formulations. Operating through the Pharmaceuticals segment, the company offers APIs in categories such as antihistamines, muscle relaxants, diuretics, iron deficiency, anti-diabetics, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, and anti-inflammatory.

Auro Laboratories Limited produces intermediates including Glibenclamide Sulphonamide, Cis-bromo benzoate, Cis-Tosylate, 2-ethoxy Benzoic Acid, 3,4,5-trimethoxy Benzoic Acid, and 5-bromo Phthalide. The company also provides toll/custom manufacturing services for APIs and intermediates on a contract basis. With a strong international presence, it exports mainly to Southeast Asia, the Middle East, and Europe, including countries like Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom.

Best Pharma Stocks Under 200 – FAQ

Here are some of the Best Stock Research Articles listed based on Top Sectors (Industries), Market Cap, and Fundamental Analysis Factors:

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.